Muscarinic Receptors as Targets for Metronomic Therapy in Ovarian Cancer-Reference-Cited by-同舟云学术

Muscarinic Receptors as Targets for Metronomic Therapy in Ovarian Cancer

Published:2023-12-30 Issue:3 Volume:25 Page:225-230
ISSN:1307-671X
Container-title:Düzce Tıp Fakültesi Dergisi
language:
Short-container-title:

Author:

SÖYLEMEZ Fatma¹^ORCID,TÜRKSEVEN Çağatay Han²^ORCID

Affiliation:

1. Mersin Üniversitesi Tıp Fakültesi Temel Tıp Bilimleri Bölümü Tıbbi Biyoloji ve Genetik Anabilim Dalı

2. Mersin Üniversitesi Tıp Fakültesi Temel Tıp Bilimleri Bölümü Biyofizik Anabilim Dalı

Abstract

Aim: In this study, the effects of muscarinic acetylcholine receptor (mAChR) agonist carbachol on the proliferation of cisplatin-resistant (A2780cis) and cisplatin-free (SKOV-3) ovarian cancer cell line were for the first time investigated to further evaluate the potential therapeutic effect of metronomic chemotherapy. Material and Methods: The inhibitory effect of carbachol on cell proliferation was detected using the xCELLigence Real-Time Cell Analyzer (RTCA) dual plate (DP) system. A preliminary study was conducted to determine the dose of carbachol 100 µM, cisplatin 1 µM, and two combination studies were carried out with 100 µM carbachol + cisplatin 1 µM and 100 µM carbachol + 10 µM atropine, over cancer cells without drugs was used as the control group. The cell proliferation curve was monitored for 96 hours. The cell index value of inhibition in cell proliferation was automatically measured every hour for each well using RTCA 1.2.1 software. Results: Co-administration of carbachol with cisplatin caused a decrease in cell number in both A2780cis and SKOV-3 cell lines in a time-dependent manner (p

Publisher

Duzce Medical Journal

Subject

General Medicine

Reference19 articles.

1. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer. 2007;7(2):79-94.

2. Zhang Q, Madden NE, Wong AST, Chow BKC, Lee LTO. The Role of endocrine G protein-coupled receptors in ovarian cancer progression. Front Endocrinol (Lausanne). 2017;8:66.

3. Gutkind JS, Novotny EA, Brann MR, Robbins KC. Muscarinic acetylcholine receptor subtypes as agonist-dependent oncogenes. Proc Natl Acad Sci USA. 1991;88(1):4703-7.

4. Español AJ, Jacob G, Dmytrenko G, Sales ME. Muscarinic activation enhances the anti-proliferative effect of paclitaxel in murine breast tumor cells. Anticancer Agents Med Chem. 2013;13(8):1273-9.

5. Aydın B, Tulunay A, Ekşioğlu-Demiralp E, Kan B, Cabadak H. Effects of carbachol on apoptosis in human chronic myelogenous leukemic K562 cell line. Marmara Med J. 2019;32(1):38-43.